news
Sonelokimab shows promise in Phase II psoriasis trial
In the trial, 57 percent of patients with moderate to severe psoriasis treated with 120mg of sonelokimab achieved total skin clearance in 24 weeks.
List view / Grid view
Therapeutics
news
Scientists show 3D printed tablet porosity can regulate drug release
Investigators suggest using 3D printing to adjust tablet porosity could allow for personalised medicines to be made at the point-of-care.
news
AstraZeneca’s Tagrisso: first medicine approved in the UK under Project Orbis
Tagrisso (osimertinib) was approved for an indication extension after it reduced risk of death by over 80 percent in certain early-stage non-small cell lung cancer patients.
news
Charles River Laboratories generates $824 million in first quarter
Charles River Laboratories International’s first quarter revenue was approximately 17 percent higher in Q1 2021, with organic revenue growth of 13 percent.
news
EC approves Xtandi™ for third prostate cancer indication
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
news
Nasal spray shown to be effective in reducing COVID-19 transmission
The algae-derived NasitrolTM nasal spray reduced the incidence of COVID-19 in intensive care unit (ICU) workers to one percent in a clinical trial.
news
Kineret® improves clinical outcomes in hospitalised patients with COVID-19 pneumonia
Treating moderate to severe COVID-19 pneumonia patients with poor prognosis with Kineret® (anakinra) prevented death and progression to severe respiratory failure.
news
Global mass spectrometry market to value $7.3 billion by 2028
With roughly a fifth of the mass spectrometry market made up by pharma and biotech, growing R&D investment and technological breakthroughs in mass spectrometers will contribute to market growth.
news
Remestemcel-L reduces ARDS mortality in those under 65 years old
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.
![A cryomicroneedle patch ready for deployment [Credit: Chang et al. /DOI number: 10.1038/s41551-021-00720-1].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/cryomicroneedle-patch-300x278.jpg)
![A cryomicroneedle patch ready for deployment [Credit: Chang et al. /DOI number: 10.1038/s41551-021-00720-1].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/cryomicroneedle-patch-e1620132484839.jpg)
news
Novel cryomicroneedle patch successfully delivers therapeutic cells in mice
Researchers have developed a new generation of microneedle technology which allows for the intradermal delivery of living cells in a minimally invasive manner.
news
EMA to assess if Olumiant should be authorised for hospitalised COVID-19 patients
The EMA will conduct an accelerated assessment and issue its decision on whether Olumiant (baricitinib) can be used in hospitalised COVID-19 patients by July.
news
COVID-19 manufacturing requirements are lucrative for CMOs, says GlobalData
A new report shows half the drugs and all the vaccines approved for emergency use in 2020 had an associated contract manufacturing agreement.
news
Highest British business award goes to cannabis drug developer, GW Pharmaceuticals
The Queen’s Award for Enterprise in Innovation was awarded to GW for leadership in cannabinoid science and development of prescription cannabis-based medicines.
news
100 percent recovery rate for COVID-19 patients treated with Zofin™
The first ten patients in a Phase I trial of Zofin™ have recovered and been discharged, the trial will now expand with an additional 65 participants.
news
Acceleron receives FDA Notice of Noncompliance
The Notice of Noncompliance gives Acceleron 30 days to submit the required clinical trial results information to ClinicalTrials.Gov or face financial penalties.
